Emergent Biosolutions Inc (EBS) financials
Emergent Biosolutions revenue and earnings by year
Emergent Biosolutions's revenue was $743 million in the fiscal year to December 31, 2025, down 28.8% from the year before. Net income was $52.6 million, 7.1% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 4.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.74 | 1.04 | 1.05 | 1.12 | 1.77 | 1.58 | 1.11 | 0.78 | 0.56 | 0.49 |
| Revenue growth | -28.8% | -0.5% | -6.1% | -37.0% | 12.4% | 42.6% | 41.4% | 39.5% | 14.8% | — |
| Gross profit | 0.42 | 0.36 | 0.34 | 0.42 | 1.03 | 1.04 | 0.67 | 0.46 | 0.37 | 0.36 |
| Gross margin | 56.1% | 34.7% | 32.8% | 38.0% | 57.8% | 66.0% | 60.8% | 58.8% | 66.5% | 74.2% |
| Operating income | 0.10 | -0.11 | -0.73 | -0.17 | 0.34 | 0.44 | 0.11 | 0.09 | 0.12 | 0.11 |
| Operating margin | 13.5% | -10.4% | -69.2% | -15.2% | 19.2% | 27.8% | 10.3% | 11.5% | 22.2% | 21.6% |
| Net income | 0.05 | -0.19 | -0.76 | -0.21 | 0.22 | 0.31 | 0.05 | 0.06 | 0.08 | 0.05 |
| Net margin | 7.1% | -18.3% | -72.5% | -18.9% | 12.4% | 19.4% | 4.9% | 8.0% | 14.7% | 10.6% |
| Diluted EPS | $0.93 | -$3.60 | -$14.85 | -$4.24 | $4.07 | $5.66 | $1.04 | $1.22 | $1.71 | $1.05 |
| Free cash flow | 0.15 | 0.04 | -0.26 | -0.15 | 0.10 | 0.40 | 0.10 | -0.03 | 0.15 | -0.02 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open EBS in Markets.
How Emergent Biosolutions makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Medical Countermeasures MCM Product | $168M | 71.7% |
| Commercial Product | $52.4M | 22.4% |
| All Other Revenue | $13.9M | 5.9% |
See also: EBS valuation and P/E history · EBS returns
No forecast, no recommendation. This page describes Emergent Biosolutions Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.